Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Changes
... 15 Artifacts Summary
.... 15.1 AbsenceOfExposureDefinition
.... 15.2 Adaptation
.... 15.3 BaselineMeasureEvidence
.... 15.4 BaselineMeasureReport
.... 15.5 BaselineVariablesList
.... 15.6 BookCitation
.... 15.7 BookPartCitation
.... 15.8 CertaintyOfEvidence
.... 15.9 Classification
.... 15.10 CohortDefinition
.... 15.11 Comment
.... 15.12 ComparativeBaselineMeasureEvidence
.... 15.13 ComparativeEvidence
.... 15.14 ComparativeEvidenceReport
.... 15.15 ComparativeEvidenceReportExpanded
.... 15.16 ComparativeEvidenceReportSubject
.... 15.17 ComparativeEvidenceSynthesisReport
.... 15.18 ComparativeParticipantFlowEvidence
.... 15.19 ComparatorGroup
.... 15.20 ComparatorOnlyEvidence
.... 15.21 Comparison
.... 15.22 CompositeRating
.... 15.23 ConceptualCohortDefinition
.... 15.24 ConceptualComparatorDefinition
.... 15.25 ConceptualExposureDefinition
.... 15.26 DatabaseCitation
.... 15.27 DatabaseEntryCitation
.... 15.28 DatasetCitation
.... 15.29 DateAsRating
.... 15.30 DichotomousIntendedOutcome
.... 15.31 EndpointAnalysisPlan
.... 15.32 EvidenceAssessment
.... 15.33 EvidenceList
.... 15.34 EvidenceReport
.... 15.35 EvidenceReportPackage
.... 15.36 EvidenceReportSubject
.... 15.37 EvidenceSynthesisEvidence
.... 15.38 ExposureGroup
.... 15.39 GroupAssignment
.... 15.40 GroupR6
.... 15.41 Guideline
.... 15.42 InterventionOnlyEvidence
.... 15.43 JournalArticleCitation
.... 15.44 M11ReportContainer
.... 15.45 M11ReportSection01
.... 15.46 M11ReportSection02
.... 15.47 M11ReportSection03
.... 15.48 M11ReportSection04
.... 15.49 M11ReportSection05
.... 15.50 M11ReportSection06
.... 15.51 M11ReportSection07
.... 15.52 M11ReportSection08
.... 15.53 M11ReportSection09
.... 15.54 M11ReportSection10
.... 15.55 M11ReportSection11
.... 15.56 M11ReportSection12
.... 15.57 M11ReportSection13
.... 15.58 M11ReportSection14
.... 15.59 MetaanalysisEligibilityCriteria
.... 15.60 MetaanalysisOutcomeDefinition
.... 15.61 MetaanalysisStudyGroup
.... 15.62 NetEffectContribution
.... 15.63 NetEffectContributionList
.... 15.64 NetEffectContributions
.... 15.65 NetEffectEstimate
.... 15.66 NonComparativeEvidence
.... 15.67 OutcomeDefinition
.... 15.68 OutcomeImportance
.... 15.69 OutcomeList
.... 15.70 OutcomeMeasureReport
.... 15.71 OutcomeVariablesList
.... 15.72 ParticipantFlowEvidence
.... 15.73 ParticipantFlowEvidenceVariable
.... 15.74 ParticipantFlowReasonEvidenceVariable
.... 15.75 ParticipantFlowReport
.... 15.76 ParticipantFlowVariablesList
.... 15.77 PICOSpecification
.... 15.78 PICOTaggedComposition
.... 15.79 PICOTaggedEvidence
.... 15.80 PreprintCitation
.... 15.81 Rating
.... 15.82 Recommendation
.... 15.83 RecommendationAction
.... 15.84 RecommendationEligibilityCriteria
.... 15.85 RecommendationJustification
.... 15.86 RecommendationPlan
.... 15.87 RecommendationRating
.... 15.88 ResearchStudyDataDictionary
.... 15.89 ResearchStudySite
.... 15.90 ResearchStudySupport
.... 15.91 RiskOfBias
.... 15.92 SearchResults
.... 15.93 SearchStrategy
.... 15.94 SingleStudyEvidence
.... 15.95 SoaPlanDefinition
.... 15.96 SoftwareCitation
.... 15.97 StatisticModel
.... 15.98 StudyComponent
.... 15.99 StudyDesign
.... 15.100 StudyEligibilityCriteria
.... 15.101 StudyGroup
.... 15.102 StudyRegistryRecord
.... 15.103 SummaryOfFindings
.... 15.104 SummaryOfNetEffect
.... 15.105 SystematicReview
.... 15.106 SystematicReviewEligibilityCriteria
.... 15.107 SystematicReviewExcludedStudies
.... 15.108 SystematicReviewIncludedStudies
.... 15.109 VariableDefinition
.... 15.110 WebPageCitation
.... 15.111 ArtifactAssessmentCompared
.... 15.112 ArtifactAssessmentDateAsRating
.... 15.113 ArtifactPublicationStatus
.... 15.114 ArtifactRecorder
.... 15.115 CharacteristicTiming
.... 15.116 CiteAs
.... 15.117 EvidenceVariableHandlingDetail
.... 15.118 GuidelineRegistration
.... 15.119 NumberAnalyzed
.... 15.120 RelatesToClassifier
.... 15.121 RelatesToWithQuotation
.... 15.122 RelativeOutcomeImportance
.... 15.123 RelevantForAutomatedMatching
.... 15.124 ResearchStudyExcludedStudy
.... 15.125 ResearchStudyIncludedStudy
.... 15.126 ResearchStudyIsLowInterventionTrial
.... 15.127 ResearchStudyIsRareDisease
.... 15.128 ResearchStudyNumberOfStudiesIdentified
.... 15.129 ResearchStudyNumberOfStudiesIncluded
.... 15.130 ResearchStudySaeReportingMethod
.... 15.131 ResearchStudySearchStrategy
.... 15.132 ResearchStudySponsorConfidentialityStatement
.... 15.133 ResearchStudyStudyAmendment
.... 15.134 ResearchStudySystematicReviewEligibilityCriteria
.... 15.135 StatisticModelExpression
.... 15.136 StatisticModelIncludeIf
.... 15.137 Desirability Codes Value Set
.... 15.138 EBMonFHIR Profile Name Value Set
.... 15.139 Evidence Rating System Classifier Codes Value Set
.... 15.140 PICO Classification Value Set
.... 15.141 Recommendation Justification Classifier Codes Value Set
.... 15.142 Research Study Document Types Value Set
.... 15.143 ResearchStudy Classifier Value Set
.... 15.144 Search Strategy Characteristic Value Set
.... 15.145 Desirability Code System
.... 15.146 EBMonFHIR Profile Name Code System
.... 15.147 Evidence Rating System Classifier Code System
.... 15.148 Research Study Document Types Code System
.... 15.149 Search Strategy Characteristic Code System
.... 15.150 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 15.151 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.152 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 15.153 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 15.154 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 15.155 179899
.... 15.156 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 15.157 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 15.158 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 15.159 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 15.160 19967827 Wonder woman was Argentine and her real name was Evita.
.... 15.161 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 15.162 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 15.163 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 15.164 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 15.165 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 15.166 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 15.167 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 15.168 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 15.169 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 15.170 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 15.171 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 15.172 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 15.173 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 15.174 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 15.175 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 15.176 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 15.177 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 15.178 27979893 6. Glycemic Targets.
.... 15.179 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 15.180 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 15.181 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 15.182 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 15.183 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 15.184 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 15.185 30467172 Finding my inner Wonder Woman.
.... 15.186 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.187 34871555 What Can Wonder Woman Teach Radiologists?
.... 15.188 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 15.189 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 15.190 367832
.... 15.191 367833
.... 15.192 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 15.193 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 15.194 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 15.195 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 15.196 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.197 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.198 Add-on Amlodipine at 6 weeks
.... 15.199 Adults with diabetes mellitus type 2
.... 15.200 Adults with type 2 diabetes and CVD and CKD
.... 15.201 Adults with type 2 diabetes and established CVD (but no CKD)
.... 15.202 Adverse event free and hypertension control
.... 15.203 Adverse event free and hypertension control at 12 weeks
.... 15.204 Adverse Events Report for NCT03421379
.... 15.205 Adverse Events Report for NCT03640312
.... 15.206 Age
.... 15.207 Age with comparator
.... 15.208 Age with intervention
.... 15.209 Aircraft Type
.... 15.210 Aircraft Type with comparator
.... 15.211 Aircraft Type with intervention
.... 15.212 Altitude
.... 15.213 Altitude comparing intervention vs. comparator
.... 15.214 Altitude for enrolled group
.... 15.215 Altitude for screened group
.... 15.216 Altitude with comparator
.... 15.217 Altitude with intervention
.... 15.218 Analyzed Group in PARACHUTE Trial
.... 15.219 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 15.220 Baseline Characteristics Report for NCT03421379
.... 15.221 Baseline Characteristics Report for NCT03640312
.... 15.222 Baseline Characteristics Report for QUARTET Trial
.... 15.223 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.224 Baseline Measures List for PARACHUTE Trial
.... 15.225 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 15.226 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 15.227 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 15.228 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 15.229 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.230 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 15.231 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.232 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.233 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 15.234 Candesartan 8 mg once daily
.... 15.235 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.236 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 15.237 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.238 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.239 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.240 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.241 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.242 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 15.243 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.244 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.245 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.246 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.247 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.248 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.249 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.250 Citation for EBMonFHIR Implementation Guide
.... 15.251 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.252 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 15.253 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.254 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 15.255 Comparative Evidence Report for QUARTET USA Trial
.... 15.256 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.257 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.258 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.259 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 15.260 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.261 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.262 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.263 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.264 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.265 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 15.266 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 15.267 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 15.268 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 15.269 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 15.270 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 15.271 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 15.272 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 15.273 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 15.274 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 15.275 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 15.276 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 15.277 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 15.278 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 15.279 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 15.280 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.281 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.282 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.283 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.284 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 15.285 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.286 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 15.287 ComparatorDefinition: Standard care
.... 15.288 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.289 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.290 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 15.291 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 15.292 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.293 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.294 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.295 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.296 Composite Rating of FOI 153881 for Project FOI 112280
.... 15.297 Computable_Publishing_LLC
.... 15.298 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 15.299 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.300 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.301 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.302 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.303 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 15.304 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 15.305 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 15.306 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 15.307 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 15.308 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 15.309 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 15.310 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 15.311 ConceptualCohortDefinition: Nonfatal stroke
.... 15.312 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter
.... 15.313 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges
.... 15.314 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 15.315 ConceptualCohortDefinition: Severe obesity
.... 15.316 ConceptualCohortDefinition: T1DM or T2DM
.... 15.317 ConceptualCohortDefinition: T1DM-specific criteria
.... 15.318 ConceptualCohortDefinition: T2DM-specific criteria
.... 15.319 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 15.320 ConceptualCohortDefinition_Cardiovascular_event
.... 15.321 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.322 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 15.323 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.324 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 15.325 COVID_19PneumoniaHospitalizedAdult
.... 15.326 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.327 CTIS2024-516402-32-00 Eligibility Criteria
.... 15.328 CTIS2024-516402-32-00 Primary Outcome 1
.... 15.329 CTIS2024-516402-32-00 Secondary Outcome 1
.... 15.330 CTIS2024-516402-32-00 Secondary Outcome 2
.... 15.331 CTIS2024-516402-32-00 Secondary Outcome 3
.... 15.332 CTIS2024-516402-32-00 Secondary Outcome 4
.... 15.333 CTIS2024-516402-32-00 Secondary Outcome 5
.... 15.334 CTIS2024-516402-32-00 Secondary Outcome 6
.... 15.335 CTIS2024-516402-32-00 Secondary Outcome 7
.... 15.336 CTIS2024-516402-32-00 Secondary Outcome 8
.... 15.337 DatabaseCitation: Citation for FEvIR Platform
.... 15.338 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.339 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 15.340 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 15.341 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 15.342 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 15.343 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 15.344 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 15.345 declined randomization in PARACHUTE Study
.... 15.346 deemed unsuitable by investigator in PARACHUTE Trial
.... 15.347 Delany-Moretlwe 2022 clinical trial
.... 15.348 Diabetes treatment medication
.... 15.349 Diastolic blood pressure at 12 weeks
.... 15.350 DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure
.... 15.351 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 15.352 DichotomousIntendedOutcome: New onset depression
.... 15.353 DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke
.... 15.354 DichotomousIntendedOutcome: Remission of diabetes
.... 15.355 DichotomousIntendedOutcome: Treatment with opioids
.... 15.356 DIO: Mortality
.... 15.357 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 15.358 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 15.359 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 15.360 Eligibility criteria for NMA_Diabetes
.... 15.361 Eligibility Criteria for QUARTET USA Trial
.... 15.362 Enrolled Group for QUARTET USA Trial
.... 15.363 Enrolled Group PARACHUTE Trial
.... 15.364 Ethnic Group
.... 15.365 Ethnic Group with comparator
.... 15.366 Ethnic Group with intervention
.... 15.367 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 15.368 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.369 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.370 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 15.371 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 15.372 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.373 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.374 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 15.375 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.376 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.377 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.378 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.379 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.380 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.381 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.382 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 15.383 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.384 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.385 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.386 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 15.387 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.388 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.389 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.390 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.391 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.392 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 15.393 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.394 EvidenceReportSectionCode Value Set
.... 15.395 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.396 EvidenceVariable Handling Extension Value Set
.... 15.397 EvidenceVariable: case_id
.... 15.398 EvidenceVariable: Patient id
.... 15.399 EvidenceVariable: Time of measurement
.... 15.400 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.401 Excluded from PARACHUTE Study
.... 15.402 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 15.403 ExposureVariable: Age (as continuous variable)
.... 15.404 ExposureVariable: Body Mass Index (as continuous variable)
.... 15.405 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 15.406 ExposureVariable: pht013093.v1.p1 RACE
.... 15.407 ExposureVariable: pht013093.v1.p1 SEX
.... 15.408 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 15.409 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 15.410 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 15.411 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 15.412 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 15.413 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 15.414 ExposureVariable: pht013094.v1.p1 Source_Type
.... 15.415 Family History of Parachute Use
.... 15.416 Family History of Parachute Use with comparator
.... 15.417 Family History of Parachute Use with intervention
.... 15.418 Frequent Flier
.... 15.419 Frequent Flier with comparator
.... 15.420 Frequent Flier with intervention
.... 15.421 GLP-1 RA Group in Adults with type 2 diabetes
.... 15.422 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 15.423 Glucagon Hydrochloride Solution (Active Comparator)
.... 15.424 Glucagon Nasal Powder (Experimental)
.... 15.425 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 15.426 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 15.427 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 15.428 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.429 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.430 GroupAssignment: GLP-1 RA vs. Standard care
.... 15.431 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 15.432 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 15.433 GroupAssignment: Non Participants vs. Enrolled Participants
.... 15.434 GroupAssignment: Quadpill vs. Candesartan
.... 15.435 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 15.436 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 15.437 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 15.438 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 15.439 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 15.440 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.441 Health Survey Score Total
.... 15.442 Health Survey Score Total comparing intervention vs. comparator
.... 15.443 Health Survey Score Total with comparator
.... 15.444 Health Survey Score Total with intervention
.... 15.445 Health Survey Score-Mental Health Subscore
.... 15.446 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 15.447 Health Survey Score-Mental Health Subscore with comparator
.... 15.448 Health Survey Score-Mental Health Subscore with intervention
.... 15.449 Health Survey Score-Physical Health Subscore
.... 15.450 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 15.451 Health Survey Score-Physical Health Subscore with comparator
.... 15.452 Health Survey Score-Physical Health Subscore with intervention
.... 15.453 Health-related Quality of Life (NCT03640312)
.... 15.454 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 15.455 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.456 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.457 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 15.458 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.459 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.460 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.461 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.462 Height
.... 15.463 Height with comparator
.... 15.464 Height with intervention
.... 15.465 High Blood Pressure Medication Value Set
.... 15.466 History of Acrophobia
.... 15.467 History of Acrophobia with comparator
.... 15.468 History of Acrophobia with intervention
.... 15.469 History of Broken Bones
.... 15.470 History of Broken Bones with comparator
.... 15.471 History of Broken Bones with intervention
.... 15.472 History of Parachute Use
.... 15.473 History of Parachute Use with comparator
.... 15.474 History of Parachute Use with intervention
.... 15.475 Hypertension Control at 12 weeks
.... 15.476 ICD-10-GM Terminale Codes
.... 15.477 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 15.478 Injury Severity Score 30 days after Impact with comparator
.... 15.479 Injury Severity Score 30 days after Impact with intervention
.... 15.480 Injury Severity Score on Impact comparing intervention vs. comparator
.... 15.481 Injury Severity Score on Impact with comparator
.... 15.482 Injury Severity Score on Impact with intervention
.... 15.483 International vs Domestic Flight
.... 15.484 International vs Domestic Flight with comparator
.... 15.485 International vs Domestic Flight with intervention
.... 15.486 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.487 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 15.488 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.489 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.490 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.491 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.492 Investigator
.... 15.493 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 15.494 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 15.495 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.496 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.497 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.498 Jumping from aircraft with empty backpack
.... 15.499 Jumping from aircraft with parachute
.... 15.500 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.501 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.502 M11 IGBJ Protocol Example Eligibility Criteria
.... 15.503 M11 Report for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.504 M11 Report for M11ResearchStudy Template
.... 15.505 M11 Report Section 1 (Protocol Summary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.506 M11 Report Section 1 (Protocol Summary) for M11ResearchStudy Template
.... 15.507 M11 Report Section 10 (Statistical Considerations) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.508 M11 Report Section 10 (Statistical Considerations) for M11ResearchStudy Template
.... 15.509 M11 Report Section 11 (Trial Oversight) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.510 M11 Report Section 11 (Trial Oversight) for M11ResearchStudy Template
.... 15.511 M11 Report Section 12 (Supporting Details) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.512 M11 Report Section 12 (Supporting Details) for M11ResearchStudy Template
.... 15.513 M11 Report Section 13 (Glossary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.514 M11 Report Section 13 (Glossary) for M11ResearchStudy Template
.... 15.515 M11 Report Section 14 (References) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.516 M11 Report Section 14 (References) for M11ResearchStudy Template
.... 15.517 M11 Report Section 2 (Introduction) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.518 M11 Report Section 2 (Introduction) for M11ResearchStudy Template
.... 15.519 M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.520 M11 Report Section 3 (Trial Objectives and Associated Estimands) for M11ResearchStudy Template
.... 15.521 M11 Report Section 4 (Trial Design) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.522 M11 Report Section 4 (Trial Design) for M11ResearchStudy Template
.... 15.523 M11 Report Section 5 (Trial Population) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.524 M11 Report Section 5 (Trial Population) for M11ResearchStudy Template
.... 15.525 M11 Report Section 6 (Trial Intervention) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.526 M11 Report Section 6 (Trial Intervention) for M11ResearchStudy Template
.... 15.527 M11 Report Section 7 (Participant Discontinuation) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.528 M11 Report Section 7 (Participant Discontinuation) for M11ResearchStudy Template
.... 15.529 M11 Report Section 8 (Trial Assessments) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.530 M11 Report Section 8 (Trial Assessments) for M11ResearchStudy Template
.... 15.531 M11 Report Section 9 (Adverse Events) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.532 M11 Report Section 9 (Adverse Events) for M11ResearchStudy Template
.... 15.533 M11ResearchStudy Template
.... 15.534 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.535 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.536 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.537 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.538 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.539 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.540 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.541 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.542 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.543 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.544 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.545 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.546 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.547 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.548 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.549 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.550 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.551 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.552 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.553 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.554 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.555 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.556 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.557 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.558 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.559 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.560 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.561 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.562 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.563 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.564 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.565 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.566 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.567 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.568 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.569 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.570 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.571 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.572 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.573 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.574 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.575 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.576 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.577 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.578 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.579 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.580 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.581 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.582 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.583 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.584 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.585 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.586 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.587 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.588 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.589 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.590 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.591 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.592 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.593 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.594 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.595 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.596 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.597 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.598 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.599 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.600 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 15.601 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 15.602 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.603 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.604 Mean Change in Serum Creatinine (NCT03640312)
.... 15.605 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 15.606 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.607 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.608 Mean Change in Serum Potassium (NCT03640312)
.... 15.609 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 15.610 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.611 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.612 Mean Change in Serum Sodium (NCT03640312)
.... 15.613 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 15.614 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.615 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.616 Mean Diastolic Blood Pressure (NCT03640312)
.... 15.617 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.618 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.619 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.620 Mean Systolic Blood Pressure (NCT03640312)
.... 15.621 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.622 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.623 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.624 Median Age of Parachute Intervention Group
.... 15.625 Medication Adherence (NCT03640312)
.... 15.626 Medication Adherence at 12 weeks
.... 15.627 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 15.628 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.629 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.630 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.631 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.632 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 15.633 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.634 Mortality at 14 days
.... 15.635 NCT03421379 Eligibility Criteria
.... 15.636 NCT03640312 Eligibility Criteria
.... 15.637 NetEffectContribution for ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.638 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.639 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.640 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.641 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.642 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.643 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 15.644 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 15.645 NetEffectEstimate for SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.646 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 15.647 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 15.648 NHANES LBXGLU Variable Definition Cohort Definition
.... 15.649 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 15.650 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 15.651 NHANES SEQN Respondent Sequence Number
.... 15.652 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 15.653 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 15.654 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 15.655 NT-proBNP Study Data Dictionary
.... 15.656 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 15.657 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 15.658 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.659 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.660 Organ support-free days
.... 15.661 Outcome Importance Rating 100 of All-cause mortality
.... 15.662 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 15.663 Outcome Importance Rating 5 of New onset depression
.... 15.664 Outcome Importance Rating 5 of Remission of diabetes
.... 15.665 Outcome Importance Rating 5 of Treatment with opioids
.... 15.666 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 15.667 Outcome Importance Rating of DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.668 Outcome Importance Rating of DichotomousIntendedOutcome: New onset depression for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.669 Outcome Importance Rating of DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.670 Outcome Importance Rating of DichotomousIntendedOutcome: Remission of diabetes for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.671 Outcome Importance Rating of DichotomousIntendedOutcome: Treatment with opioids for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.672 Outcome Importance Rating of Mortality for Bariatric Surgery Patients
.... 15.673 Outcome Measure List for QUARTET USA Trial
.... 15.674 Outcome Measure Report for QUARTET USA Trial
.... 15.675 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.676 Outcome Measures Report for NCT03421379
.... 15.677 Outcome Measures Report for NCT03640312
.... 15.678 Outcome Variables List for PARACHUTE Trial
.... 15.679 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 15.680 Outcome: Death or Major Traumatic Injury on Impact
.... 15.681 Outcome: Injury Severity Score 30 days after Impact
.... 15.682 Outcome: Injury Severity Score on Impact
.... 15.683 OutcomeDefinition: Injury Severity Score on Impact
.... 15.684 OutcomeDefinition: All-cause mortality
.... 15.685 OutcomeDefinition: All-cause mortality
.... 15.686 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 15.687 OutcomeDefinition: Body weight
.... 15.688 OutcomeDefinition: Body weight
.... 15.689 OutcomeDefinition: Cardiovascular mortality
.... 15.690 OutcomeDefinition: Cardiovascular mortality
.... 15.691 OutcomeDefinition: Diabetes in remission
.... 15.692 OutcomeDefinition: Diabetic ketoacidosis
.... 15.693 OutcomeDefinition: End-stage kidney disease
.... 15.694 OutcomeDefinition: End-stage kidney disease
.... 15.695 OutcomeDefinition: Genital infection
.... 15.696 OutcomeDefinition: HbA1c at 12 months
.... 15.697 OutcomeDefinition: HbA1c at 24 months
.... 15.698 OutcomeDefinition: HbA1c at 36 months
.... 15.699 OutcomeDefinition: HbA1c at 6 months
.... 15.700 OutcomeDefinition: HbA1c at 60 months
.... 15.701 OutcomeDefinition: Health-related quality of life
.... 15.702 OutcomeDefinition: Health-related quality of life
.... 15.703 OutcomeDefinition: Heart failure
.... 15.704 OutcomeDefinition: Heart failure
.... 15.705 OutcomeDefinition: Mortality at 14 days
.... 15.706 OutcomeDefinition: New onset depression
.... 15.707 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.708 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.709 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 15.710 OutcomeDefinition: Nonfatal stroke
.... 15.711 OutcomeDefinition: Nonfatal stroke
.... 15.712 OutcomeDefinition: Serious hyperglycaemia
.... 15.713 OutcomeDefinition: Serious hyperglycaemia
.... 15.714 OutcomeDefinition: Severe gastrointestinal events
.... 15.715 OutcomeDefinition: Severe gastrointestinal events
.... 15.716 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.717 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.718 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 15.719 OutcomeVariable: HbA1c at 12 months
.... 15.720 OutcomeVariable: HbA1c at 24 months
.... 15.721 OutcomeVariable: HbA1c at 36 months
.... 15.722 OutcomeVariable: HbA1c at 6 months
.... 15.723 OutcomeVariable: HbA1c at 60 months
.... 15.724 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.725 OutcomeVariable: New onset depression
.... 15.726 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 15.727 OutcomeVariable: Remission of diabetes
.... 15.728 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.729 OutcomeVariable_Additional_GI_surgical_procedure
.... 15.730 OutcomeVariable_All_cause_mortality
.... 15.731 OutcomeVariable_Treatment_with_opioids
.... 15.732 PARACHUTE Trial baseline characteristics
.... 15.733 PARACHUTE Trial non participants
.... 15.734 PARACHUTE trial participant flow report
.... 15.735 PARACHUTE Trial Participants
.... 15.736 PARACHUTE Trial Participants assigned an empty backpack
.... 15.737 PARACHUTE trial participants assigned parachute
.... 15.738 PARACHUTE Trial Participants available for randomization
.... 15.739 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 15.740 PARACHUTE Trial Participants randomized into groups
.... 15.741 PARACHUTE Trial Participants randomized into groups for screened group
.... 15.742 PARACHUTE Trial Participants randomized into groups with comparator
.... 15.743 PARACHUTE Trial Participants randomized into groups with intervention
.... 15.744 PARACHUTE Trial Participants that completed 30 day follow up
.... 15.745 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 15.746 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 15.747 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 15.748 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 15.749 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 15.750 PARACHUTE Trial Participants that declined randomization
.... 15.751 PARACHUTE Trial Participants with no contact at 30 days
.... 15.752 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 15.753 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 15.754 PARACHUTE Trial Results
.... 15.755 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.756 Parachute vs Empty Backpack in PARACHUTE Trial
.... 15.757 Participant Flow Report for NCT03421379
.... 15.758 Participant Flow Report for NCT03640312
.... 15.759 Participant Flow Report for QUARTET USA Trial
.... 15.760 Participant Flow Variables List for PARACHUTE Trial
.... 15.761 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 15.762 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 15.763 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 15.764 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 15.765 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 15.766 ParticipantFlowMeasure: Exclusion from analysis
.... 15.767 ParticipantFlowMeasure: Inclusion in analysis
.... 15.768 Participants Excluded from PARACHUTE Study
.... 15.769 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 15.770 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 15.771 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.772 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.773 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.774 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 15.775 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.776 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.777 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379
.... 15.778 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 15.779 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 15.780 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.781 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.782 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 15.783 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 15.784 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.785 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.786 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 15.787 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.788 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.789 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.790 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.791 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.792 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.793 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.794 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.795 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.796 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.797 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.798 Placebo
.... 15.799 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.800 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.801 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 15.802 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 15.803 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 15.804 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.805 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.806 Proportion of Patients With Hypertension Control (NCT03640312)
.... 15.807 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 15.808 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 15.809 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 15.810 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 15.811 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 15.812 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 15.813 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.814 Quadpill once daily
.... 15.815 QUARTET USA Trial Control Group
.... 15.816 QUARTET USA Trial Quadpill group
.... 15.817 randomized into groups for PARACHUTE Trial
.... 15.818 Rate of Adverse Events of Special Interest (NCT03640312)
.... 15.819 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 15.820 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.821 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.822 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 15.823 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 15.824 Reasons for exclusion from QUARTET USA Trial
.... 15.825 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 15.826 Recommendation Justification Code System
.... 15.827 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 15.828 Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.829 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 15.830 Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.831 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 15.832 Remdesivir
.... 15.833 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 15.834 ResearchStudy Classifier Code System
.... 15.835 Results Section for NCT03421379
.... 15.836 Results Section for NCT03640312
.... 15.837 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.838 Risk of Bias Assessment of PARACHUTE trial
.... 15.839 Risk Of Bias Type Value Set
.... 15.840 Screened Group PARACHUTE Trial
.... 15.841 Search Strategy for NMA_Diabetes
.... 15.842 SearchResults: PubMed search for Wonder Woman
.... 15.843 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 15.844 SearchStrategy: PubMed search for Wonder Woman
.... 15.845 Sex
.... 15.846 Sex with comparator
.... 15.847 Sex with intervention
.... 15.848 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.849 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 15.850 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 15.851 Spanish or English Value Set
.... 15.852 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.853 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 15.854 StudyEligibilityCriteria for M11Report Example
.... 15.855 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 15.856 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 15.857 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.858 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 15.859 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 15.860 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 15.861 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 15.862 Summary of Findings - QUARTET USA Trial
.... 15.863 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 15.864 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.865 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.866 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.867 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.868 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.869 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.870 Systolic blood pressure at 12 weeks
.... 15.871 Time to integration of results in a recommendation
.... 15.872 VariableDefinition: Comparator
.... 15.873 VariableDefinition: Condition(s)
.... 15.874 VariableDefinition: Date of birth
.... 15.875 VariableDefinition: Date of measurement
.... 15.876 VariableDefinition: Gender
.... 15.877 VariableDefinition: NTproBNP
.... 15.878 VariableDefinition: Unit
.... 15.879 Velocity
.... 15.880 Velocity comparing intervention vs. comparator
.... 15.881 Velocity for enrolled group
.... 15.882 Velocity for non participant group
.... 15.883 Velocity with comparator
.... 15.884 Velocity with intervention
.... 15.885 WebPageCitation: A HEvKA Update Summary
.... 15.886 Weight
.... 15.887 Weight with comparator
.... 15.888 Weight with intervention